NEW YORK (GenomeWeb) – When Greenwood Genetics Center announced last week that it is now offering Affymetrix's US Food and Drug Administration-cleared CytoScan Dx Assay to its clinicians for chromosomal microarray analysis, it became the first laboratory in the US to do so.

Though the Greenwood, SC-based center already offers a laboratory-developed test based on Affymetrix's research use only CytoScan HD product, the addition of the CytoScan Dx Assay appeals to users for multiple reasons, according to Alka Chaubey, director of the center's cytogenetics laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.